title: Sequence-specific bacterial growth inhibition by peptide nucleic acid targeted to the mRNA binding site of 16S rRNA.
abstract: Peptide nucleic acid (PNA) targeted to the functional domains of 23S rRNA can inhibit translation and cell growth. However, effective inhibition of translation and cell growth using 16S rRNA-targeted PNA has still not been achieved. Here, we report that PNA targeted to the functional site of 16S rRNA could inhibit both gene expression in vitro and bacterial growth in pure culture with sequence specificity. We used 10-mer PNAs conjugated with a cell-penetrating peptide, which targeted the mRNA binding site at the 3' end of 16S rRNA. Using 0.6 microM of the peptide-PNAs, cell-free ss-galactosidase production decreased by 50%, whereas peptide-PNAs with one or two mismatches to the target sequence showed much weaker inhibition effects. To determine the growth inhibition and bactericidal effects of the peptide-PNA conjugate, we performed OD measurement and viable cell counting. We observed dose- and sequence-dependent inhibition of cell growth and bactericidal effects. These growth inhibitory effects are observed both in the Gram-negative bacterium of Escherichia coli and the Gram-positive bacteria Bacillus subtilis and Corynebacterium efficiens, although inhibitory concentrations were different for each bacterial species. These results present possibilities for 16S rRNA sequence-based specific bacterial growth inhibition using a peptide-PNA conjugate.
authors: Department of Social and Environmental Engineering, Hiroshima University, Higashi-Hiroshima, Japan.
authors: Masashi
authors: M
authors: Hatamoto
authors: Kazufumi
authors: K
authors: Nakai
authors: Akiyoshi
authors: A
authors: Ohashi
authors: Hiroyuki
authors: H
authors: Imachi
mesh_terms: D001412:Bacillus subtilis / Q000187:drug effects / Q000254:growth & development / Q000378:metabolism; D001483:Base Sequence; D001665:Binding Sites / Q000235:genetics; D003352:Corynebacterium / Q000187:drug effects / Q000254:growth & development / Q000378:metabolism; D020118:Cupriavidus necator / Q000187:drug effects / Q000254:growth & development / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004926:Escherichia coli / Q000187:drug effects / Q000235:genetics / Q000254:growth & development*; D004927:Escherichia coli Infections / Q000188:drug therapy / Q000378:metabolism; D006801:Humans; D020135:Peptide Nucleic Acids / Q000235:genetics / Q000378:metabolism* / Q000627:therapeutic use; D014176:Protein Biosynthesis / Q000187:drug effects; D012329:RNA, Bacterial / Q000235:genetics / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D012336:RNA, Ribosomal, 16S / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*
chemical_list: D020135:Peptide Nucleic Acids; D012329:RNA, Bacterial; D012333:RNA, Messenger; D012336:RNA, Ribosomal, 16S